The case for cancer-associated fibroblasts: essential elements in cancer drug discovery?

Future Drug Discovery

卷:4

Christopher Moraes¹  Anne-Marie Fortier¹  Gabrielle Brewer²  Morag Park² 

[1] Morris Goodman Cancer Research Centre, McGill University, 1160 Avenues des Pins, Montréal, QC, H3A 0G4, Canada;

[2] 1Rosalind &

关键词: biomaterials;    cancer;    cancer associated fibroblast;    extracellular matrix;    mechanobiology;    microenvironment;   

DOI  :  10.4155/fdd-2021-0004

来源: DOAJ

【 摘 要 】

Although cancer-associated fibroblasts (CAFs) have gained increased attention for supporting cancer progression, current CAF-targeted therapeutic options are limited and failing in clinical trials. As the largest component of the tumor microenvironment (TME), CAFs alter the biochemical and physical structure of the TME, modulating cancer progression. Here, we review the role of CAFs in altering drug response, modifying the TME mechanics and the current models for studying CAFs. To provide new perspectives, we highlight key considerations of CAF activity and discuss emerging technologies that can better address CAFs; and therefore, increase the likelihood of therapeutic efficacy. We argue that CAFs are crucial components of the cancer drug discovery pipeline and incorporating these cells will improve drug discovery success rates.

【 授权许可】

Unknown